Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

42 results about "D lactate" patented technology

D-lactate is produced by bacteria residing in the colon when carbohydrates are not completely absorbed in the small intestine. When large amounts of D-lactate are present, individuals can experience metabolic acidosis, altered mental status (from drowsiness to coma), and a variety of other neurologic symptoms, particularly dysarthria and ataxia.

Composition with disintoxicating and liver-protecting effects and application thereof in food and health-care food

The invention relates to a composition with disintoxicating and liver-protecting effects, which comprises the following raw materials in percentage by mass: 0.15 to 5 percent of crucumin, 0.04 to 1.0 percent of zinc lactate, 10 to 50 percent of glutamine, 10 to 50 percent of alanine and 10 to 50 percent of xylooligosaccharide. It is proved that, by an animal experiment and a human tasting experiment, the composition increases the alcohol dehydrogenase and acetaldehyde dehydrogenase content of a body and rapidly decomposes alcohol, so that the composition has the effects of promoting alcohol metabolism in a liver and reducing the alcohol concentration and active oxygen concentration in a blood; and the composition increases an endurance capacity of a human body to the alcohol, reduces the discomforts such as headache, nausea, vomiting and the like due to the alcohol, and reduces the damages of the alcohol to the liver. The composition can be prepared into food and health-care food with the disintoxicating and liver-protecting effects, can be used as a disintoxicating product for preventing and improving excessive drinking, and can be used as an adjuvant therapy product for an alcoholic liver, a fatty liver due to the alcohol or non-alcohol and protecting the liver; and the composition has the advantages of safety, non-toxicity and a reliable curative effect.
Owner:SHANDONG MINGREN FURUIDA PHARMA

In-situ implantation drug delivery system of naltrexone microsphere-hydrogel matrix

The invention discloses an in-situ implantation drug delivery system of microsphere-hydrogel matrix of detoxification drug naltrexone, belonging to the field of medicinal preparation. The drug naltrexone is embedded in microspheres of biodegradable materials polylactic acid / glycolic acid polymer; the microspheres disperse in reverse temperature sensitive hydrosol of methylcellulose; the hydrosol is solidified into a hydrogel matrix at body temperature during hypodermic injection to form a composite system of microsphere-hydrogel matrix and to control the release of naltrexone. The invention integrates the advantages of medicine carrying controlled release particles and temperature sensitive gel matrix in-situ implantation system, realizes injected implantation, realizes release at a constant speed for 60 days after implantation, and can adjust drug release speed by adjusting the content of naltrexone microspheres in hydrogel, thus having great significance in improving clinical application effect of naltrexone and in solving the problem of relapse in the detoxification process.
Owner:TSINGHUA UNIV

Lactate sensor

The invention relates to a lactate sensor, and specifically a lactate sensor capable of accurately measuring a lactate concentration in a short period of time. The lactate sensor includes an insulating substrate, an electrode system including at least a working electrode and a counter electrode provided on the substrate, and a reagent layer provided on the electrode system. The reagent layer contains lactate oxidase, a mediator, and N-(2-acetamide)-2-aminoethanesulfonic acid.
Owner:ARKRAY INC

Method for preparing panaxoside and panaxynol through enzymatic zymotechnics

The invention discloses a method for preparing panaxoside and panaxynol through enzymatic zymotechnics. The method comprises the following steps: cleaning Changbai mountain ginseng, drying the ginseng at 50 to 60 DEG C, and crushing the ginseng to be 40 meshes; clustering raw material powder in hands, releasing namely dispersing the raw material power, adding mineral water to the raw material power, soaking the raw material power for 18 hours, and adjusting the PH value to be 4.5 to 6.5; putting mixed liquor into an enzymatic zymotechnics tank, adding enzymatic zymotechnics liquid to perform enzymatic zymotechnics, setting the enzymatic zymotechnics temperature to be 35 DEG C and the enzymatic zymotechnics time to be 72 hours, stirring and oxygenating once every 4 hours, and controlling the PH value to be 3.5 to 6.2; performing frame filtering, performing spray drying on supernate, ensuring that the drying temperature does not exceed 65 DEG C, and controlling the moisture to be lower than 7 percent to obtain powder; crushing the powder to be 120-mesh powder, then performing Co60 irradiation sterilization, and packing and warehousing finished products. The method is convenient in technology, easy to operate, low in energy consumption, clean and environment-friendly.
Owner:珲春绿源参业生物科技有限公司

Strains of escherichia coli modified by metabolic engineering to produce chemical compounds from hydrolyzed lignocellulose, pentoses, hexoses and other carbon sources

The present invention refers to the new Escherichia coli strains denominated JU15, JU15A, LL26 and MS04 and their derivatives that produce metabolites, particularly D-lactate, L-lactate or ethanol, with high yield and selectivity from a wide variety of carbon sources, such as culture media with a high xylose content (as the main carbon source) and, in particular, media formulated with hydrolyzed vegetables, such as sugarcane bagasse, agave bagasse and fast-growing grasses, and a wide variety of agricultural and industrial wastes, such as whey or forestry wastes, celluloses, grasses, agave bagasse, paper wastes, shavings and sawdust, shrubs and generally any material derived from lignocellulose. These strains use the production of the metabolite of interest (especially D-lactate, L-lactate or ethanol) as the only way of regenerating the reducing power. The invention also refers to fermentation methods to produce these metabolites from media with a diversity of carbon sources, including glucose, lactose or xylose.
Owner:UNIV NAT AUTONOMA DE MEXICO

Fluid therapy with L-lactate and/or pyruvate anions

Electrolyte solutions are provided which are useful in electrolyte and fluid therapy, parenteral nutrition and dialysis. The Na:Cl ratio is normalized, plasma and cellular pH are normalized and cellular cofactor ratios are normalized in a manner which decreases toxicity over prior art solutions.
Owner:BTG INT LTD

Composition with disintoxicating and liver-protecting effects and application thereof in food and health-care food

The invention relates to a composition with disintoxicating and liver-protecting effects, which comprises the following raw materials in percentage by mass: 0.15 to 5 percent of crucumin, 0.04 to 1.0 percent of zinc lactate, 10 to 50 percent of glutamine, 10 to 50 percent of alanine and 10 to 50 percent of xylooligosaccharide. It is proved that, by an animal experiment and a human tasting experiment, the composition increases the alcohol dehydrogenase and acetaldehyde dehydrogenase content of a body and rapidly decomposes alcohol, so that the composition has the effects of promoting alcohol metabolism in a liver and reducing the alcohol concentration and active oxygen concentration in a blood; and the composition increases an endurance capacity of a human body to the alcohol, reduces the discomforts such as headache, nausea, vomiting and the like due to the alcohol, and reduces the damages of the alcohol to the liver. The composition can be prepared into food and health-care food withthe disintoxicating and liver-protecting effects, can be used as a disintoxicating product for preventing and improving excessive drinking, and can be used as an adjuvant therapy product for an alcoholic liver, a fatty liver due to the alcohol or non-alcohol and protecting the liver; and the composition has the advantages of safety, non-toxicity and a reliable curative effect.
Owner:SHANDONG MINGREN FURUIDA PHARMA

Flushing fluid containing sorbitol and mannitol and suitable for urologic surgeries

The invention relates to the field of medical reagents and discloses a flushing fluid containing sorbitol and mannitol and suitable for urologic surgeries. The flushing fluid is prepared from components as follows: 2.5wt%-2.9wt% of sorbitol, 0.5wt%-0.6wt% of mannitol and the balance of water for injection. The flushing fluid is mainly prepared from sorbitol and mannitol serving as main ingredients, adopts perfusion therapy through a proper urinary system instrument via the urethra and is applicable to flushing in the transurethral resection of the prostate and other urologic surgeries. The flushing fluid has the advantages as follows: 1) the flushing fluid is non-hemolytic; 2) the flushing fluid can also be used for diabetics; 3) the flushing fluid has a good diuretic function; 4) the flushing fluid can prevent blood coagulation in the surgeries, and a good intra-operative view can be kept; 5) the flushing fluid serving as a washing fluid used after the surgeries has a good blood coagulation prevention function; 6) the flushing fluid facilitates rapid excretion of sorbitol due to higher content of mannitol, and the potential risks of the sorbitol liver metabolite, namely, lactic acid are reduced.
Owner:JIMIN HEALTH MANAGEMENT CO LTD

Radioactive sustained-release particle and preparation and use thereof

InactiveCN101322849AEasy to killSolve the problem of targeted drug deliveryRadioactive preparation carriersRadioactive preparation formsSide effectMedicine
The invention discloses a radioactive slow-release particle and a preparation method and the application thereof, pertaining to the field of radiation medicine. The particle mainly consists of <32> P-chromium phosphate and poly-L-lactic acid and can better solve the problem of targeted delivery of drugs in the treatment of tumors. The transplant of the particles in a tumor body or around a tumor can increase the local concentration of the drug, prolong the time of drug action and reduce systemic toxic and side effects.
Owner:王自正 +7

Hyperpolarized lactate contrast agent for determination of LDH activity

A hyperpolarized MR imaging medium and a method of 13C-MR detection using a hyperpolarized MR imaging medium for the determination of lactate dehydrogenase (LDH) activity. The contrast media comprises hyperpolarised [13C, 2H] lactate.
Owner:GENERAL ELECTRIC CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products